DVAX - Dynavax Technologies - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

DVAX is currently covered by 3 analysts with an average price target of $21.54. This is a potential upside of $10.72 (99.08%) from yesterday's end of day stock price of $10.82.

Dynavax Technologies's activity chart (see below) currently has 72 price targets and 65 ratings on display. The stock rating distribution of DVAX is 80% BUY, 13.33% HOLD and 6.67% SELL.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 38.45% with an average time for these price targets to be met of 245.4 days.

Highest price target for DVAX is $31, Lowest price target is $12, average price target is $21.5.

Most recent stock forecast was given by ROY BUCHANAN from JMP on 07-May-2025. First documented stock forecast 12-Dec-2014.

Currently out of the existing stock ratings of DVAX, 12 are a BUY (80%), 2 are a HOLD (13.33%), 1 are a SELL (6.67%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$31

$19.94 (180.29%)

$27

3 months 6 days ago
(07-May-2025)

0/6 (0%)

$21.28 (218.93%)

Buy

$31

$19.94 (180.29%)

$31

5 months 23 days ago
(21-Feb-2025)

6/20 (30%)

$17.67 (132.56%)

334

Hold

$12

$-0.82 (-6.40%)

$20

6 months 2 days ago
(11-Feb-2025)

0/4 (0%)

$-1.2 (-9.09%)

Sell

$12

$0.94 (8.50%)

$15

6 months 2 days ago
(11-Feb-2025)

1/3 (33.33%)

$-0.7 (-5.51%)

56

Buy

$30

$18.94 (171.25%)

$20

3 years 9 months 8 days ago
(05-Nov-2021)

4/12 (33.33%)

$13.84 (85.64%)

368

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is DVAX (Dynavax Technologies) average time for price targets to be met?

On average it took 245.4 days on average for the stock forecasts to be realized with a an average price target met ratio 38.45

Which analyst has the current highest performing score on DVAX (Dynavax Technologies) with a proven track record?

BRIAN ABRAHAMS

Which analyst has the most public recommendations on DVAX (Dynavax Technologies)?

Brian Abrahams works at RBC and has 23 price targets and 16 ratings on DVAX

Which analyst is the currently most bullish on DVAX (Dynavax Technologies)?

Roy Buchanan with highest potential upside - $19.94

Which analyst is the currently most reserved on DVAX (Dynavax Technologies)?

Madhu Kumar with lowest potential downside - -$0.82

Dynavax Technologies in the News

Dynavax (DVAX) Q2 Revenue Jumps 29%

Key Points Dynavax Technologies (NASDAQ:DVAX) exceeded analyst expectations in Q2 2025, reporting GAAP revenue of $95.4 million and GAAP diluted EPS of $0.14. HEPLISAV-B, Dynavax’s two-dose adult hepatitis B vaccine, set another sales record in Q2 2025, becoming the company’s key growth driver with $91.9 million in GAAP net product revenue. Guidance for full-year 2025...

Dynavax Technologies (DVAX) Q2 Earnings and Revenues Beat Estimates

Dynavax Technologies (DVAX) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.08 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +16.67%. A quarter ago, it was expected that...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?